Search Orphan Drug Designations and Approvals
-
Generic Name: | nelarabine | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trade Name: | Arranon | ||||||||||||||||
Date Designated: | 08/10/2004 | ||||||||||||||||
Orphan Designation: | Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma | ||||||||||||||||
Orphan Designation Status: | Designated/Approved | ||||||||||||||||
Sponsor: |
Novartis Pharmaceuticals Corp. One Health Plaza East Hanover, New Jersey 07936 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
||||||||||||||||
Marketing approved: |
|||||||||||||||||
1 | Generic Name: | nelarabine |
---|---|---|
Trade Name: | Arranon | |
Marketing Approval Date: | 10/28/2005 | |
Approved Labeled Indication: | Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens | |
Exclusivity End Date: | 10/28/2012 | |
Exclusivity Protected Indication* : | ||
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-